Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2026 04:00 ET | Source: Alvotech

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...
June 08, 2026 04:00 ET | Source: Alvotech

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
June 08, 2026 04:00 ET | Source: Alvotech

Matvæla- og lyfjastofnun Bandaríkjanna tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir AVT16, fyrirhugaða hliðstæðu við Entyvio

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefði tekið til umsagnar og afgreiðslu umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT16, fyrirhugaða...
June 04, 2026 04:00 ET | Source: Alvotech

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...
June 04, 2026 04:00 ET | Source: Alvotech

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
June 04, 2026 04:00 ET | Source: Alvotech

Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið hafi lagt inn að nýju til Matvæla- og lyfjastofnunar Bandaríkjanna (FDA) umsóknir um leyfi til markaðssetningar í Bandaríkjunum á...
June 03, 2026 16:30 ET | Source: Alvotech

Main Results of 2026 Annual and Extraordinary General Meeting

The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg. All of the draft resolutions...
June 03, 2026 16:30 ET | Source: Alvotech

Niðurstaða aðalfundar Alvotech árið 2026

Aðalfundur Alvotech fór fram 3. júní 2026. Fundurinn var haldinn í Lúxemborg, á skrifstofu lögfræðistofunnar Arendt við Avenue John F. Kennedy 41A. Allar tillögur á dagskrá fundarins voru...
June 03, 2026 16:30 ET | Source: Alvotech

Main Results of 2026 Annual and Extraordinary General Meeting

REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House,...
June 02, 2026 16:30 ET | Source: Alvotech

Alvotech to present at upcoming investor conferences in June

REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...